Form 4: Viking Therapeutics CFO Zante Greg Reports Stock Vesting and Tax-Related Sale
Insider Transaction Report
Viking Therapeutics' Chief Financial Officer, Zante Greg, reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.
Summary
- Zante Greg, Chief Financial Officer of Viking Therapeutics, Inc. (VKTX), reported transactions involving the company's common stock.
- On July 2, 2025, 7,667 shares of common stock were acquired due to the vesting of a performance restricted stock unit (RSU) award.
- The RSU award was granted on January 3, 2025, and 33.33% vested upon the achievement of a non-financial performance goal.
- On July 3, 2025, 4,266 shares were disposed of at a weighted average price of $27.761 per share.
- This disposition was an automatic, non-discretionary sale solely to satisfy tax withholding obligations related to the RSU vesting.
- Following these transactions, Zante Greg beneficially owns 168,660 shares of Viking Therapeutics common stock.
Sentiment
Score: 6
Explanation: The report indicates the achievement of a non-financial performance goal leading to RSU vesting, which is positive. The subsequent sale of shares was for tax purposes, a routine and expected event, thus maintaining a neutral to slightly positive sentiment.
Positives
- The vesting of 7,667 performance restricted stock units indicates the achievement of a non-financial performance goal by the company, reflecting progress in specific operational or strategic areas.
Negatives
- A total of 4,266 shares were sold, reducing the direct beneficial ownership of the Chief Financial Officer, although this was for tax purposes.
Future Outlook
No forward-looking statements or guidance are provided in this insider transaction report.
Industry Context
This Form 4 filing details a routine insider transaction related to equity compensation, which is common across all industries for publicly traded companies. It does not provide information relevant to broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Disclosure of insider equity transactions provides transparency regarding management's holdings and compensation, which can inform investment decisions.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of grant for the performance restricted stock unit award. |
| 07/02/2025 | Date of vesting for 33.33% of the performance restricted stock unit award upon achievement of a non-financial performance goal, resulting in the acquisition of 7,667 shares. |
| 07/03/2025 | Date of sale of 4,266 shares to satisfy tax withholding obligations related to the RSU vesting. |
Keywords
Viking Therapeutics, VKTX, Zante Greg, CFO, SEC Form 4, Insider Transaction, Stock Vesting, Restricted Stock Units, RSU, Equity Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.